Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report

• DOI: 10.1038/s41409-018-0153-1
• Publication Date: 2018-03-08T12:56:02Z
• Authors: Jakob R Passweg; Helen Baldomero; Peter Bader; Grzegorz W. Basak; Chiara Bonini; Rafael Duarte; Carlo Dufour; Nicolaus Kröger; Jürgen Kuball; Arjan Lankester; Silvia Montoto; Arnon Nagler; John A. Snowden; Jan Styczynski; Mohamad Mohty
• Keywords: Hematology

Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency continued activity in this field with 43,636 HCT 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers 49 countries 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid 25,618 (65%; 20% solid tumors 1516 (4%; 2% non-malignant 2459 (6%; 85% allogeneic). There remarkable leveling off use unrelated donor being replaced haploidentical HCT. Continued growth marrow failure, AML, MPN seen, whereas MDS appears stable. Allogeneic vary trend increases NHL decreases Hodgkin lymphoma myeloma. Trends CLL are not clear, recent after decrease activity. HCT, myeloma continues to expand but stable lymphoma. notable increase autoimmune disease. These data reflect most advances field, which some trends changes likely be related development non-transplant technologies.